Immuron reveals anti-Covid potential, raises $28 million

Hot on the heels of reporting anti-Covid-19 action by one of the drugs it is developing, biotechnology company Immuron has raised $28 million (US$20 million) from institutional investors. On Tuesday the company reported its Travelan product for the prevention of travellers’ diarrhoea demonstrated neutralising activity against severe acute respiratory syndrome coronovirus-2, the virus that causes…